A cost analysis of diabetic lower-extremity ulcers

被引:163
作者
Harrington, C
Zagari, MJ
Corea, J
Klitenic, J
机构
[1] Lewin Grp, Falls Church, VA 22042 USA
[2] Johnson & Johnson Consumer Prod Inc, Hlth Econ, Raritan, NJ USA
关键词
D O I
10.2337/diacare.23.9.1333
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - Our objectives were to 1) estimate the prevalence of diabetes and diabetic lower-extremity ulcers in the Medicare population, 2) characterize Medicare population-specific costs for lower-extremity ulcer episodes, and 3) evaluate potential cost savings associated with better healing of lower-extremity ulcers. RESEARCH DESIGN AND METHODS - Prevalence and costs of diabetic lower-extremity ulcers were obtained by an analysis of Medicare claims data from 1995 and 1996 Standard Analytic Files (5% sample). RESULTS - Medicare expenditures for lower-extremity ulcer patients were on average 3 times higher than those for Medicare patients in general ($15,309 vs. $5,226). Lower-extremity ulcer-related spending accounted for 24% of total spending for lower-extremity ulcer patients. Most of the ulcer-related costs accrued on the inpatient side (73.7%); proportionately smaller amounts went to physicians and nursing home facilities. lo determine the potential effect of better diabetic ulcer management, a model was created that estimated the impact on costs with improved healing rates. Improving the 20-week healing rate from 31 to 40% would save Medicare $189 per episode. CONCLUSIONS - Lower-extremity ulcers cost the Medicare system $1.5 billion in 1995. Any wound care intervention that could prevent even a small percentage of wounds from progressing to the stage at which inpatient care is required may have a favorable cost effect on the Medicare system.
引用
收藏
页码:1333 / 1338
页数:6
相关论文
共 5 条
[1]  
Glover J L, 1997, Adv Wound Care, V10, P33
[2]  
Holzer SES, 1998, CLIN THER, V20, P169
[3]   Healing of diabetic neuropathic foot ulcers receiving standard treatment - A meta-analysis [J].
Margolis, DJ ;
Kantor, J ;
Berlin, JA .
DIABETES CARE, 1999, 22 (05) :692-695
[4]   Incidence, outcomes, and cost of foot ulcers in patients with diabetes [J].
Ramsey, SD ;
Sandhu, N ;
Newton, K ;
Reiber, GE ;
Blough, D ;
Wagner, EH ;
McCullough, DK .
DIABETES CARE, 1999, 22 (03) :382-387
[5]   RANDOMIZED PROSPECTIVE DOUBLE-BLIND TRIAL IN HEALING CHRONIC DIABETIC FOOT ULCERS - CT-102 ACTIVATED PLATELET SUPERNATANT, TOPICAL VERSUS PLACEBO [J].
STEED, DL ;
GOSLEN, JB ;
HOLLOWAY, GA ;
MALONE, JM ;
BUNT, TJ ;
WEBSTER, MW .
DIABETES CARE, 1992, 15 (11) :1598-1604